{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:40:53Z","timestamp":1761741653426,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T00:00:00Z","timestamp":1633910400000},"content-version":"vor","delay-in-days":283,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2021]]},"DOI":"10.6061\/clinics\/2021\/e3146","type":"journal-article","created":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T18:56:20Z","timestamp":1634583380000},"page":"e3146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Phase II trial of humanized anti-Lewis Y monoclonal antibody for advanced hormone receptor-positive breast cancer that progressed following endocrine therapy"],"prefix":"10.1016","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6080-7429","authenticated-orcid":false,"given":"Laura","family":"Testa","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5666-5261","authenticated-orcid":false,"given":"Max","family":"Mano","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5617-1042","authenticated-orcid":false,"given":"Roberto Jun","family":"Arai","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5818-922X","authenticated-orcid":false,"given":"Renata Colombo","family":"Bonadio","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1222-9016","authenticated-orcid":false,"given":"Sergio V.","family":"Serrano","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9870-9015","authenticated-orcid":false,"given":"Marina M Costa","family":"Zorzetto","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5463-5517","authenticated-orcid":false,"given":"Susanne","family":"Crocamo","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2788-2616","authenticated-orcid":false,"given":"Oren","family":"Smaletz","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4145-8598","authenticated-orcid":false,"given":"Ruffo","family":"Freitas-Junior","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0065-2194","authenticated-orcid":false,"given":"Paulo M.","family":"Hoff","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"6","key":"10.6061\/clinics\/2021\/e3146_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.6061\/clinics\/2021\/e3146_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40487-019-00105-0","article-title":"Invasive Lobular Breast Cancer as a Distinct Disease: Implications for Therapeutic Strategy","volume":"8","author":"Luveta","year":"2020","journal-title":"Oncol Ther"},{"issue":"5.5","key":"10.6061\/clinics\/2021\/e3146_bib3","first-page":"552","article-title":"NCCN Guidelines Updates: Breast Cancer","volume":"17","author":"Telli","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"20","key":"10.6061\/clinics\/2021\/e3146_bib4","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and Letrozole in Advanced Breast Cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.6061\/clinics\/2021\/e3146_bib5","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.6061\/clinics\/2021\/e3146_bib6","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med"},{"issue":"25","key":"10.6061\/clinics\/2021\/e3146_bib7","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+\/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.6061\/clinics\/2021\/e3146_bib8","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.6061\/clinics\/2021\/e3146_bib9","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3","volume":"36","author":"Slamon","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.6061\/clinics\/2021\/e3146_bib10","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"issue":"16","key":"10.6061\/clinics\/2021\/e3146_bib11","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1200\/JCO.2002.10.057","article-title":"Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment","volume":"20","author":"Howell","year":"2002","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.6061\/clinics\/2021\/e3146_bib12","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1200\/JCO.2002.10.058","article-title":"Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial","volume":"20","author":"Osborne","year":"2002","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.6061\/clinics\/2021\/e3146_bib13","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s12282-020-01095-y","article-title":"The efficacy of sequential second-line endocrine therapies (ETs) in postmenopausal estrogen receptor-positive and HER2-negative metastatic breast cancer patients with lower sensitivity to initial ETs","volume":"27","author":"Iwamoto","year":"2020","journal-title":"Breast Cancer"},{"issue":"5","key":"10.6061\/clinics\/2021\/e3146_bib14","doi-asserted-by":"crossref","first-page":"R780","DOI":"10.1186\/bcr1305","article-title":"High expression of Lewis y\/b antigens is associated with decreased survival in lymph node negative breast carcinomas","volume":"7","author":"Madjd","year":"2005","journal-title":"Breast Cancer Res"},{"issue":"4","key":"10.6061\/clinics\/2021\/e3146_bib15","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1189\/jlb.68.4.511","article-title":"Activation-dependent expression of the blood group-related lewis Y antigen on peripheral blood granulocytes","volume":"68","author":"Dettke","year":"2000","journal-title":"J Leukoc Biol"},{"issue":"12","key":"10.6061\/clinics\/2021\/e3146_bib16","first-page":"3254","article-title":"Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors","volume":"60","author":"Scott","year":"2000","journal-title":"Cancer Res"},{"issue":"7","key":"10.6061\/clinics\/2021\/e3146_bib17","first-page":"2183","article-title":"Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Le(y)-related cell surface antigens","volume":"50","author":"Hellstr\u00f6m","year":"1990","journal-title":"Cancer Res"},{"issue":"11","key":"10.6061\/clinics\/2021\/e3146_bib18","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1200\/JCO.2000.18.11.2282","article-title":"Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors","volume":"18","author":"Saleh","year":"2000","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.6061\/clinics\/2021\/e3146_bib19","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1089\/02724570050031167","article-title":"Breast cancer progression and expression of blood group-related tumor-associated antigens","volume":"19","author":"Steplewska-Mazur","year":"2000","journal-title":"Hybridoma"},{"issue":"17","key":"10.6061\/clinics\/2021\/e3146_bib20","first-page":"4804","article-title":"In vivo biodistribution of a humanized anti-Lewis Y monoclonal antibody (hu3S193) in MCF-7 xenografted BALB\/c nude mice","volume":"60","author":"Clarke","year":"2000","journal-title":"Cancer Res"},{"issue":"8","key":"10.6061\/clinics\/2021\/e3146_bib21","first-page":"1281","article-title":"PET imaging of (86)Y-labeled anti-Lewis Y monoclonal antibodies in a nude mouse model: comparison between (86)Y and (111)In radiolabels","volume":"42","author":"L\u00f6vqvist","year":"2001","journal-title":"J Nucl Med"},{"issue":"5","key":"10.6061\/clinics\/2021\/e3146_bib22","first-page":"1720","article-title":"Imaging and phase I study of 111In- and 90Y-labeled anti-LewisY monoclonal antibody B3","volume":"6","author":"Pai-Scherf","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"26","key":"10.6061\/clinics\/2021\/e3146_bib23","doi-asserted-by":"crossref","first-page":"12957","DOI":"10.1073\/pnas.91.26.12957","article-title":"Specificity analysis of blood group Lewis-y (Le(y)) antibodies generatedagainst synthetic and natural Le(y) determinants","volume":"91","author":"Kitamura","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.6061\/clinics\/2021\/e3146_bib24","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1158\/1078-0432.CCR-07-0284","article-title":"A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen","volume":"13","author":"Scott","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.6061\/clinics\/2021\/e3146_bib25","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1097\/JTO.0b013e3181560dcc","article-title":"Targeting Lewis Y (Le(y)) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levels","volume":"2","author":"Krug","year":"2007","journal-title":"J Thorac Oncol"},{"issue":"10","key":"10.6061\/clinics\/2021\/e3146_bib26","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.2007.13.5822","article-title":"Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT","volume":"26","author":"Chia","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.6061\/clinics\/2021\/e3146_bib27","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ygyno.2015.05.023","article-title":"A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant\/refractory ovarian, fallopian tube and primary peritoneal carcinoma","volume":"138","author":"Smaletz","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.6061\/clinics\/2021\/e3146_bib28","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1470-2045(19)30804-6","article-title":"CDK4\/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis","volume":"21","author":"Gao","year":"2020","journal-title":"Lancet Oncol"}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222002253?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222002253?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T07:08:12Z","timestamp":1761721692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1807593222002253"},"secondary":[{"URL":"https:\/\/www.scielo.br\/j\/clin\/a\/gkZsXqbYPNB66qqhy5qpBzD\/?lang=en","label":"SCIELO"},{"URL":"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8478140\/","label":"PMC"},{"URL":"https:\/\/www.clinicsjournal.com\/article\/phase-ii-trial-of-humanized-anti-lewis-y-monoclonal-antibody-for-advanced-hormone-receptor-positive-breast-cancer-that-progressed-following-endocrine-therapy\/","label":"CLINICS"}]},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":28,"alternative-id":["S1807593222002253"],"URL":"https:\/\/doi.org\/10.6061\/clinics\/2021\/e3146","relation":{},"ISSN":["1807-5932"],"issn-type":[{"type":"print","value":"1807-5932"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II trial of humanized anti-Lewis Y monoclonal antibody for advanced hormone receptor-positive breast cancer that progressed following endocrine therapy","name":"articletitle","label":"Article Title"},{"value":"Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.6061\/clinics\/2021\/e3146","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 CLINICS. Published by Elsevier Spain","name":"copyright","label":"Copyright"}],"article-number":"e3146"}}